文献速递流行病学与生物统计真实世界研究与卫生经济

45至49岁成人结直肠癌人群健康筛查策略:一项随机临床试验

Population Health Colorectal Cancer Screening Strategies in Adults Aged 45 to 49 Years: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01

该随机临床试验纳入20 509名45至49岁平均风险个体,比较四种外展策略对结直肠癌筛查参与率的影响。结果显示,与常规护理默认邮寄粪便免疫化学检测(FIT)相比,三种主动选择策略的6个月筛查完成率均显著更低;在双模式主动选择组中,结肠镜检查完成率高于FIT。

要点

  • 常规护理默认邮寄FIT组6个月筛查参与率为26.2%,高于三种主动选择策略组(14.5%–17.4%)。
  • 三种主动选择策略组与常规护理组相比,筛查参与率差异均有统计学显著性(P < .001)。
  • 双模式主动选择组中,完成结肠镜检查者占12.0%,完成FIT者占5.6%。

核心结论

  • 在45至49岁平均风险个体中,三种主动选择干预措施的结直肠癌筛查完成率均低于常规护理。

研究设计与样本

  • 随机临床试验,纳入20 509名45至49岁平均风险结直肠癌的初级保健患者,按1:1:1:1随机分配至四种外展策略之一;试验于2022年5月2日至2022年5月13日进行,随访至2022年11月13日。

主要发现

  • 总体筛查参与率为18.6%(3816/20 509)。
  • FIT-only主动选择组参与率为16.4%(841/5131),较常规护理组率差为-9.8%(95% CI,-11.3%至-8.2%)。
  • 结肠镜-only主动选择组参与率为14.5%(743/5127),较常规护理组率差为-11.7%(95% CI,-13.2%至-10.1%)。
  • 双模式(FIT或结肠镜)主动选择组参与率为17.4%(890/5125),较常规护理组率差为-8.9%(95% CI,-10.5%至-7.4%)。
  • 常规护理默认邮寄FIT组参与率为26.2%(1342/5126);所有主动选择组与常规护理组比较P < .001。

关键数值与推荐

  • 双模式主动选择组完成任何筛查的比例为17.4%,单模式主动选择组合并为15.4%,率差为-1.8%(95% CI,-3.0%至-0.1%),P = .004。
  • 在双模式主动选择组中,完成结肠镜检查者占12.0%(616/5125),完成FIT者占5.6%(288/5125),率差为-6.4%(95% CI,-7.5%至-5.3%),P < .001。
  • FIT-only主动选择组中交叉至结肠镜检查者占9.8%(502/5131);常规护理默认邮寄FIT组中交叉至结肠镜检查者占9.8%(501/5126)。
  • 结肠镜-only主动选择组中交叉至FIT者占2.7%(137/5127)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Colorectal cancer screening is now recommended at age 45 years for average-risk individuals; however, optimal outreach strategies to screen younger adults are unknown. OBJECTIVE: To determine the most effective population health outreach strategy to promote colorectal cancer screening in adults aged 45 to 49 years. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial with 20 509 participants conducted in a large health system (UCLA Health). Primary care patients aged 45 to 49 years at average risk for colorectal cancer were randomized 1:1:1:1 to 1 of 4 outreach strategies. The trial ran May 2, 2022, to May 13, 2022, with follow-up through November 13, 2022. INTERVENTIONS: Colorectal cancer screening via 1 of 4 strategies: (1) fecal immunochemical test (FIT)-only active choice; (2) colonoscopy-only active choice; (3) dual-modality (FIT or colonoscopy) active choice; and (4) usual care default mailed FIT outreach. MAIN OUTCOME AND MEASURES: Primary outcome was participation in screening (FIT or colonoscopy) at 6 months. Secondary outcome was screening modality completed. RESULTS: Among 20 509 participants (53.9% female, 4.2% Black and 50.8% non-Hispanic White; mean [SD] age, 47.4 [1.5] years), 3816 (18.6%) underwent screening. Participation was significantly lower in each of the 3 active choice groups (FIT only, 841 of 5131 [16.4%; rate difference, -9.8%; 95% CI, -11.3% to -8.2%]; colonoscopy only, 743 of 5127 [14.5%; rate difference, -11.7%; 95% CI, -13.2% to -10.1%]; dual-modality FIT or colonoscopy, 890 of 5125 [17.4%; rate difference, -8.9%; 95% CI, -10.5% to -7.4%]) than in the usual care default mailed FIT group (1342 of 5126 [26.2%]; all P < .001). Participants offered dual-modality active choice more likely completed any screening than those offered a single active choice modality (17.4% [dual-modality FIT or colonoscopy] vs 15.4% [FIT only and colonoscopy only combined]; rate difference, -1.8%; 95% CI, -3.0% to -0.1%; P = .004]). Among 5125 participants offered a choice between 2 modalities (dual-modality active choice FIT or colonoscopy), colonoscopy was more common than FIT (616 [12.0%] vs 288 [5.6%]; rate difference, -6.4%; 95% CI, -7.5% to -5.3%; P < .001). There was notable crossover in the FIT-only groups to colonoscopy (502 of 5131 [9.8%; FIT-only active choice] and 501 of 5126 [9.8%; usual care default mailed FIT]). Crossover from colonoscopy to FIT was modest (137 of 5127 [2.7%; colonoscopy-only active choice]). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, 3 different active choice interventions had lower colorectal cancer screening completion rates among individuals aged 45 to 49 years compared with usual care. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05275530.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Galoosian A, Dai H, Croymans D, et al. Population Health Colorectal Cancer Screening Strategies in Adults Aged 45 to 49 Years: A Randomized Clinical Trial. JAMA. 2025. PMID: 40758331. doi:10.1001/jama.2025.12049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。